-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Palisade Bio (NASDAQ:PALI) & Brickell Biotech (NASDAQ:BBI) Financial Survey
Palisade Bio (NASDAQ:PALI) & Brickell Biotech (NASDAQ:BBI) Financial Survey
Palisade Bio (NASDAQ:PALI – Get Rating) and Brickell Biotech (NASDAQ:BBI – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.
Insider and Institutional Ownership
7.9% of Palisade Bio shares are held by institutional investors. 11.4% of Palisade Bio shares are held by insiders. Comparatively, 4.5% of Brickell Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Get Palisade Bio alerts:Analyst Recommendations
This is a summary of recent ratings for Palisade Bio and Brickell Biotech, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Palisade Bio | 0 | 1 | 1 | 0 | 2.50 |
Brickell Biotech | 0 | 1 | 2 | 0 | 2.67 |
Earnings and Valuation
This table compares Palisade Bio and Brickell Biotech's gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Palisade Bio | $10,000.00 | 216.61 | -$26.62 million | $0.78 | 0.13 |
Brickell Biotech | $400,000.00 | 12.36 | -$39.47 million | ($13.52) | -0.13 |
Palisade Bio has higher earnings, but lower revenue than Brickell Biotech. Brickell Biotech is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Palisade Bio has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, Brickell Biotech has a beta of 0.02, meaning that its stock price is 98% less volatile than the S&P 500.
Profitability
This table compares Palisade Bio and Brickell Biotech's net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Palisade Bio | N/A | -121.31% | -54.75% |
Brickell Biotech | -643.48% | -156.10% | -128.23% |
Summary
Palisade Bio beats Brickell Biotech on 10 of the 14 factors compared between the two stocks.
About Palisade Bio
(Get Rating)
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
About Brickell Biotech
(Get Rating)
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
Palisade Bio (NASDAQ:PALI – Get Rating) and Brickell Biotech (NASDAQ:BBI – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.
Palisade Bio(纳斯达克:Pali-Get评级)和Brickell Biotech(纳斯达克:BBI-GET评级)都是小盘医疗公司,但哪种投资更好?我们将根据这两家公司的盈利能力、收益、估值、风险、机构所有权、股息和分析师建议来比较它们的实力。
Insider and Institutional Ownership
内部人与机构持股
7.9% of Palisade Bio shares are held by institutional investors. 11.4% of Palisade Bio shares are held by insiders. Comparatively, 4.5% of Brickell Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Palisade Bio 7.9%的股份由机构投资者持有。Palisade Bio 11.4%的股份由内部人士持有。相比之下,Brickell Biotech 4.5%的股份由内部人士持有。强大的机构持股表明,大型基金管理公司、捐赠基金和对冲基金相信,一家公司的长期表现将好于大盘。
Analyst Recommendations
分析师建议
This is a summary of recent ratings for Palisade Bio and Brickell Biotech, as reported by MarketBeat.com.
这是MarketBeat.com报道的Palisade Bio和Brickell Biotech最近的评级摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Palisade Bio | 0 | 1 | 1 | 0 | 2.50 |
Brickell Biotech | 0 | 1 | 2 | 0 | 2.67 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
Palisade Bio | 0 | 1 | 1 | 0 | 2.50 |
布里科尔生物技术公司 | 0 | 1 | 2 | 0 | 2.67 |
Earnings and Valuation
收益和估值
This table compares Palisade Bio and Brickell Biotech's gross revenue, earnings per share and valuation.
此表比较了Palisade Bio和Brickell Biotech的毛收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Palisade Bio | $10,000.00 | 216.61 | -$26.62 million | $0.78 | 0.13 |
Brickell Biotech | $400,000.00 | 12.36 | -$39.47 million | ($13.52) | -0.13 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
Palisade Bio | $10,000.00 | 216.61 | -2,662万元 | $0.78 | 0.13 |
布里科尔生物技术公司 | $400,000.00 | 12.36 | -3,947万元 | ($13.52) | -0.13 |
Palisade Bio has higher earnings, but lower revenue than Brickell Biotech. Brickell Biotech is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.
Palisade Bio的收益高于Brickell Biotech,但收入低于Brickell Biotech。Brickell Biotech的市盈率低于Palisade Bio,这表明它目前是两只股票中更负担得起的一只。
Volatility and Risk
波动性和风险
Palisade Bio has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, Brickell Biotech has a beta of 0.02, meaning that its stock price is 98% less volatile than the S&P 500.
Palisade Bio的贝塔系数为1.78,这意味着其股价的波动性比标准普尔500指数高78%。相比之下,Brickell Biotech的贝塔系数为0.02,这意味着其股价的波动性比标准普尔500指数低98%。
Profitability
盈利能力
This table compares Palisade Bio and Brickell Biotech's net margins, return on equity and return on assets.
此表比较了Palisade Bio和Brickell Biotech的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Palisade Bio | N/A | -121.31% | -54.75% |
Brickell Biotech | -643.48% | -156.10% | -128.23% |
净利润率 | 股本回报率 | 资产回报率 | |
Palisade Bio | 不适用 | -121.31% | -54.75% |
布里科尔生物技术公司 | -643.48% | -156.10% | -128.23% |
Summary
摘要
Palisade Bio beats Brickell Biotech on 10 of the 14 factors compared between the two stocks.
Palisade Bio在两只股票比较的14个因素中有10个超过了Brickell Biotech。
About Palisade Bio
关于Palisade Bio
(Get Rating)
(获取评级)
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Palisade Bio,Inc.是一家临床阶段的生物制药公司,专注于发现、开发和商业化口腔疗法,这些疗法针对与保护胃肠道的粘膜屏障破裂有关的严重疾病。它的主要候选治疗药物是LB1148,这是一种消化酶抑制剂的口服液配方,旨在抑制消化酶活性,并在肠应激期间保持肠道完整性,这些应激是由于流向肠道的血液减少、感染或手术造成的。该公司成立于2005年,总部设在加利福尼亚州卡尔斯巴德。
About Brickell Biotech
关于Brickell Biotech
(Get Rating)
(获取评级)
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Brickell Biotech,Inc.是一家临床阶段的制药公司,致力于开发各种处方疗法,用于治疗美国的自身免疫、炎症和其他令人衰弱的疾病。该公司开发的产品包括:已完成治疗原发性腋窝多汗症的第三阶段临床试验的索吡溴铵;用于治疗自身免疫和炎症性疾病的口服DYRK1A抑制剂BBI-02;以及用于潜在治疗自体炎症和罕见遗传性疾病的干扰素基因共价刺激物BBI-10,以及下一代激酶抑制剂。它与Carna Biosciences,Inc.,Voronoi Inc.,Bodor实验室,Inc.和Nicholas S.Bodor博士以及Anges,Inc.签订了许可和合作协议。该公司成立于2009年,总部位于科罗拉多州博尔德市。
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
接受Palisade Bio Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Palisade Bio和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧